Sanofi (NASDAQ:SNY) is one of the best low volatility stocks to buy under $50. Deutsche Bank cut the price target on Sanofi (NASDAQ:SNY) to EUR 95 from EUR 100 on June 15 and maintained a Buy rating on the shares. For reference, in its financial results for fiscal Q1 2026, Sanofi (NASDAQ:SNY) reported double-digit sales and business EPS growth. Fiscal Q1 sales growth was 13.6% at CER, while business earnings per share reached €1.88. Pharma launches sales rose by 49.6% and reached €1.2 billion, driven primarily by Ayvakit, ALTUVIIIO, and Sarclisa.
Management further reported that Dupixent sales grew by 30.8% to €4.2 billion, suggesting a solid start to 2026. Similarly, vaccine sales grew by 2.1% to €1.3 billion, benefiting from Heplisav-B. Sanofi (NASDAQ:SNY) also announced that Research and Development expenses reached €1.7 billion, up by 1.5%, while selling and general expenses reached €2.3 billion, up by 11.6%, primarily due to the effect of recent acquisitions.
Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company's operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.
While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Management further reported that Dupixent sales grew by 30.8% to €4.2 billion, suggesting a solid start to 2026. Similarly, vaccine sales grew by 2.1% to €1.3 billion, benefiting from Heplisav-B. Sanofi (NASDAQ:SNY) also announced that Research and Development expenses reached €1.7 billion, up by 1.5%, while selling and general expenses reached €2.3 billion, up by 11.6%, primarily due to the effect of recent acquisitions.
Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company's operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.
While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
4 hours ago
